<DOC>
	<DOCNO>NCT00773331</DOCNO>
	<brief_summary>This two arm study compare maintenance hemoglobin level , safety tolerability every 4 week subcutaneous administration Mircera versus epoetin beta dialysis patient chronic renal anemia . Patients randomize receive either subcutaneous Mircera ( start dose 120 , 200 360 microgram ) every 4 week subcutaneous epoetin beta accordance prescribe dose information . In group , start dose previous dose epoetin beta administer week precede first study drug administration . Patients treat 28 week follow 4 week last treatment visit . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Comparing Maintenance Hemoglobin Levels , Safety Tolerability Once Every 4 Weeks Mircera Versus Epoetin Beta Dialysis Patients With Chronic Renal Anemia .</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>male female patient , &gt; =18 year age ; chronic renal anemia ; Hb concentration 10.0 12.0 g/dL screening period ; continuous subcutaneous maintenance therapy epoetin dose AND dose interval least 12 week throughout screen . blood transfusion within previous 8 week ; poorly control hypertension ; significant acute chronic bleeding ; active malignant disease ; congestive heart failure ( NYHA Class IV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>